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Summary Positron emission tomography (PET) is more accurate than computed tomography
(CT) in the staging of non-small cell lung cancer (NSCLC). We analyzed the prognostic value of
PET for survival in NSCLC patients.
Methods: Consecutive patients with proven NSCLC with PET for staging were selected. Staging
by laboratory tests, bronchoscopy, chest X-ray, and CT was performed in all patients, leading
to a clinical stage (c-TNM) prior to PET. A separate classiﬁcation (pet-TNM) was obtained from
PET images by observers blinded to clinical data. We performed univariate survival analysis
with ECOG performance score, sex, weight loss, comorbidity, histology, c-TNM, and pet-TNM as
variables. Cox regression analysis was performed with signiﬁcant variables from the univariate
analyses.
Results: Two hundred and sixty-six patients were included, 205 men and 61 women. c-TNM
and pet-TNM were identical in 150 (56%) patients, 69 were upstaged, and 47 were downstaged
by PET. At time of analysis, 198 (74%) patients had died. Univariate analysis showed signiﬁ-
cant survival differences for ECOG performance score (0 versus 1/2), weight loss (<10% versus
≥10%), pulmonary comorbidity, c-TNM, and pet-TNM (stage IA versus IB, IIA, IIB, IIIA, IIIB, IV).
Cox regression analysis identiﬁed pet-TNM as the most signiﬁcant (p < 0.001) prognostic factor,
followed by ECOG performance score (p = 0.018).
Conclusion: Tumor stage as determined by PET is the most signiﬁcant prognostic factor for
survival in patients with NSCLC.
© 2006 Elsevier Ireland Ltd. All rights reserved.
 Preliminary results of the study presented in this manuscript were presented as a poster at the 40th Annual Meeting of the American
Society of Clinical Oncology (abstract #7227), 2004, New Orleans, USA.
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1. Introduction
Lung cancer staging is important for determining optimal
treatment and prognosis. In practice, a presumptive diag-
nosis is made on the basis of presentation, risk factors,
and physical examination. Subsequently, lung cancer stag-
ing is performed with chest radiography, bronchoscopy,
computed tomography (CT), and tests to exclude distant
metastases [1]. After that, therapy is started and a prog-
nosis can be calculated. Survival curves of non-small cell
lung cancer (NSCLC) by Mountain and Dresler were con-
structed using data from the 10 years prior to publica-
tion, i.e. data obtained with radiography, bronchoscopy, and
CT [2].
Positron emission tomography (PET) with 18F-ﬂuoro-
deoxyglucose (FDG) as a tracer is a functional imaging
technique, which appears to be valuable for staging of
NSCLC [3]. PET proved to be more accurate than CT in
distinguishing malignant from benign pulmonary nodules,
and it is the most accurate non-invasive procedure for the
detection of NSCLC metastases to mediastinal lymph nodes
and distant sites [4,5].
Whether PET has independent prognostic value has not
been evaluated but survival prediction with PET has been
subject of several studies, all with a limited number of
patients [6—13]. In the largest of these studies, 162 patients
were included, and FDG uptake within the primary tumor
2.2. Positron emission tomography
Patients had to fast for 6 h before PET scanning, but they
were allowed to drink water and take their usual med-
ications. FDG was synthesized according to Hamacher et
al. by an automated computer controlled synthesis module
[15,16]. Whole body PETwas performedwith an ECAT 951/31
or an ECAT HR+ scanner (Siemens/CTI, Knoxville, TN, USA).
Fields of view were 10.8 and 15.0 cm, respectively, with res-
olutions of 6 and 5mm full width at half maximum. Scanning
was started 90min after intravenous injection of 370 MBq of
FDG. PET images were reconstructed into coronal, sagittal,
and transverse sections, and into an upright rotating projec-
tion. Standard ECAT/CAPP software (Siemens/CTI) was used
for PET analysis.
PET scans were interpreted by an experienced nuclear
physician and a research physician experienced in the anal-
ysis of PET images. PET image interpretation was performed
blinded to all clinical data, including clinical stage (c-TNM).
For each patient, a PET stage (pet-TNM) was determined.
FDG uptake was qualitatively assessed, and a hotspot was
deﬁned as a focal increase in FDG uptake compared to the
background, not explained by physiological tracer uptake.
PET images were used to localize pulmonary, mediastinal,





























pwas strongly associated with survival [13].
We analyzed the prognostic signiﬁcance of NSCLC staging
by PET for survival and determined its relation with known




We selected consecutive patients who underwent PET for
the staging of lung cancer. The study was approved by the
Medical Ethics Committee of the Groningen University Hospi-
tal. Only patients with pathologically proven NSCLCwere eli-
gible. Patients with small-cell lung cancer as well as patients
with bronchiolo-alveolar cell carcinoma were excluded. All
patients were evaluated at the thoracic oncology unit by his-
tory, physical examination, complete blood cell count, renal
and liver function tests, chest radiography, bronchoscopy,
and CT of the chest and upper abdomen prior to PET.
Bone scans, upper abdominal ultrasound, and CT or mag-
netic resonance imaging (MRI) of the brain were performed
only in case of symptoms or signs suggestive of speciﬁc
metastases.
Before PET was performed, a clinical stage (c-TNM) was
determined in each patient using all clinical data available.
Patients with clinical stages I—IIIB were referred for PET to
determine a pet-TNM stage. Patients with clinical stage IV
were not referred for PET.
All tumor stages, both clinical and PET stages, were
described according to the revised international staging sys-
tem for NSCLC adopted by the American Joint Committee on
Cancer and the Union Internationale Contre le Cancer [14]..3. Follow-up
fter PET, patients were treated at the pulmonary oncology
epartment. Surgery was performed for stages I—IIIA,
hemoradiotherapy for stage IIIB, and chemotherapy for
tage IV.
All patients were followed for at least 1 year after the
ate of PET, unless they died earlier. Dates and causes of
eath were recorded. Duration of survival was deﬁned as
he time between the date of PET and the date of death or
ast follow-up visit.
.4. Statistical analysis
tatistical analysis was performed with SPSS 11.5 (SPSS
nc., Chicago, IL). Continuous variables are reported as
edians with ranges. Dichotomous variables are reported
s percentage with 95% conﬁdence interval (95% CI).
he McNemar test was used to compare c-TNM and pet-
NM. Univariate survival analyses were performed with
he Kaplan—Meier method and log rank test. Signiﬁcant
ariables in the univariate analyses were used for multi-
ariate analysis. Correction for interaction variables was
erformed. Multivariate analysis was performed with the
ox proportional hazards model, with forward stepwise
ovariate entry, and signiﬁcance levels of 0.05 for entry
nd 0.10 for removal. Reported p values are two-sided, and
< 0.05 is considered indicating signiﬁcance.
. Results
.1. Patients
etween October 1996 and December 2001, PET was
erformed in 399 subsequent patients with suspected
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Table 1 General characteristics of the 266 patients
Characteristics Patients
No. %









<10% of normal weight 237 89
≥10% of normal weight 29 11
Pulmonary comorbidity
None 177 67








lung cancer. We excluded 95 patients who did not
have pathologically proven NSCLC, and 38 patients
who underwent PET for treatment evaluation instead
of staging, resulting in 266 patients who were eligi-
ble for analysis. Patient characteristics are outlined in
Table 1. Histological subgroups of NSCLC are outlined in
Table 2.
c-TNM and pet-TNM were determined in all 266 patients.
In 150 (56%) patients, c-TNM and pet-TNM were identical,
while 69 (26%) patients were upstaged and 47 (18%) patients
were downstaged by PET. In two (0.8%) patients, PET was
negative; these patients were diagnosed with squamous cell
carcinoma and large cell carcinoma. A statistically signiﬁ-
cant difference was observed between c-TNM and pet-TNM
(p = 0.031).
Table 2 Pathological diagnoses of the 266 patients
Characteristics Patients
No. %
Squamous cell carcinoma 98 37
Adenocarcinoma 80 30
Large cell carcinoma 80 30
Large cell neuro-endocrine carcinoma 4 2
3.2. Treatment
First-line treatment consisted of surgery in 72 (27%)
patients, chemotherapy in 78 (29%) patients, radiotherapy
in 29 (11%) patients, a combination in 65 (24%) patients,
and no treatment in 22 (8%) patients. Tumor progression
occurred in 141 patients after a median progression free
interval of 8 months (range, 1—50 months). Of these 141
patients, 101 received second-line treatment, surgery being
in 10 patients, chemotherapy in 46 patients, radiotherapy in
41 patients, and a combination in 4 patients.
3.3. Survival and prognostic factors
At time of analysis, 198 (74%) of the 266 patients had died.
Cause of death was lung cancer in 179 patients, rectal carci-
noma in 1 patient, and intercurrent non-malignant diseases
in 18 patients. Sixty-eight patients were still alive, 10 with
and 58 without lung cancer.
The prognostic value for survival of c-TNM and pet-TNM
were analyzed. For this analysis, eight variables traditionally
regarded as being related to NSCLC survival were selected
to join c-TNM and pet-TNM in multivariate survival analysis,
in order to correct for possible confounding. These addi-
tional variables included age, sex, ECOG performance score,
weight loss prior to staging, (cardio)vascular comorbidity,Adenosquamous carcinoma 2 1
Pleomorphic carcinoma 2 1pulmonary comorbidity, and histology (squamous versus non-
squamous as well as adeno versus non-adeno). Age was the
only continuous variable; all others were dichotomous cat-
egorical variables.
As ﬁrst step, separate univariate survival analyses were
performed for each of the categorical variables (Table 3).
Of all these variables, ECOG performance score (0 ver-
sus 1/2), weight loss (<10% versus ≥10%), pulmonary
comorbidity (absent versus present), c-TNM (IA versus IB,
IIA, IIB, IIIA, IIIB, IV), and pet-TNM (IA versus IB, IIA,
Table 3 Univariate survival analyses (Kaplan—Meier
method)
Variable Log rank test
signiﬁcance



















c-TNM (IA vs. IB, IIA, IIB,
IIIA, IIIB, IV)
<0.0001
pet-TNM (IA vs. IB, IIA, IIB,
IIIA, IIIB, IV)
<0.0001
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Table 4 Cox proportional hazards model of prognostic factors
Covariate Signiﬁcance Relative riska 95% CIa
Age 0.216
Pulmonary comorbidity (absent vs. present) 0.130
Weight loss (<10% vs. ≥10%) 0.115
ECOG performance score (0 vs. 1—2) 0.018 1.43 1.06—1.92
c-TNM 0.054†
pet-TNM <0.001‡
Stage IB vs. stage IA 0.049 3.36 1.00—11.27
Stage IIA vs. stage IA 0.012 6.25 1.49—26.18
Stage IIB vs. stage IA 0.007 5.55 1.58—19.50
Stage IIIA vs. stage IA 0.001 8.19 2.49—26.94
Stage IIIB vs. stage IA <0.001 12.71 3.90—41.44
Stage IV vs. stage IA <0.001 20.23 6.32—64.63
a Relative risks and 95% conﬁdence intervals are reported for signiﬁcant covariates only.
† Overall signiﬁcance for c-TNM. Differences between c-TNM stages were likewise not signiﬁcant.
‡ Overall signiﬁcance for pet-TNM. Survival of patients in each single pet-TNM stage was signiﬁcantly different from survival of patients
in pet-TNM stage IA.
IIB, IIIA, IIIB, IV) were signiﬁcant at univariate survival
analysis.
These ﬁve signiﬁcant variables were subsequently
entered into a Cox proportional hazards model, with the
addition of the continuous variable age. Before entering, the
categorical variables were checked for proportionality by
entering them one by one as strata into the model, all other
variables being covariates. Hazard plots showed that all cat-
egorical variables were proportionally related to baseline.
After this, all categorical variables as well as the age vari-
able were entered as covariates into the Cox proportional
hazards model. Interaction variables ECOG performance
score×weight loss, ECOG performance score×pulmonary
comorbidity, and c-TNM×pet-TNM did not inﬂuence out-
comes.
In the Cox proportional hazards model (Table 4), pet-
TNM was the most signiﬁcant prognostic factor for survival
(p < 0.001, higher PET stages predicting worse survival), fol-
lowed by ECOG performance score (p = 0.018). Survival of
patients in each single pet-TNM stage was signiﬁcantly dif-
ferent from survival of patients in pet-TNM stage IA, with
an increasing hazard ratio for death for patients in subse-
quently higher stages.
Age, weight loss, and pulmonary comorbidity did not














PET proved to be an important prognostic factor, but the
procedures and tests by which these results were obtained
differed markedly. In two of the eight studies, the Cox pro-
portional hazards model was used to show that staging with
PET had a much stronger prognostic value for NSCLC than
clinical staging without PET [10,13]. In one-third study, the
prognostic value of PET was simply determined on the basis
of positive or negative PET images after treatment [9]. In
six studies, an arbitrary cut-off of the standardized uptake
value (SUV) was used to dichotomize patients into a high and
a low SUV group. SUV cut-off values were mostly determined
post hoc by calculating median SUV of the study population
or the SUV cut-off value with the highest discrimination in
survival. This resulted in cut-off values of 5, 7, 10, or 20
[6—8,11—13].
In the present study, PET images were analyzed quali-
tatively, i.e. without the use of a SUV, and we were able
to show that qualitative PET assessment had prognostic
impact. Qualitative assessment of PET results in fast and
useful information, and is the most commonly applied form
of PET analysis in daily practice. The calculation of a SUV
is useful for research purposes, but calculation increases
the amount of time needed for analysis. Furthermore, the
interpretation of a SUV in daily practice is complicated by
the fact that most studies determined a SUV cut-off values
by calculating the median SUV of the study population post
hoc, i.e. after the study had been closed. Clinicians and














ur report is the largest study on the prognostic value of
ET in NSCLC. We found tumor extension in the lung, medi-
stinal lymph nodes, and at distant sites as determined by
ET to be the most signiﬁcant prognostic factor for survival,
lthough clinical staging did approach signiﬁcance. PET,
ike any other staging modality, may produce false-negative
esults. However, the false-negative rate in the present
tudy was extremely low, i.e. 2 out of 266 patients. CT,
n the other hand, did not produce false-negative results.
he signiﬁcance of PET in our study conﬁrms the results of
ight earlier, but smaller, studies [6—13]. In these studies,aiting for a prospective study validating a previously deter-
ined generally accepted ‘standard’ SUV cut-off value. The
ext problem may be which SUV to use; it may be the max-
mum or mean SUV of the primary tumor, lymph nodes, or
ven of distant metastases. Thus, SUV is surrounded by too
any questions to simply indicate its usefulness. This clin-
cal dilemma is illustrated by two studies by Vesselle et al.
n one study, the relation between SUV and tumor prolif-
ration rate is demonstrated, but in another study, they
ound an association between tumor stage and SUV which
isappeared after correction of tumor uptake for lesion size
17,18]. These uncertainties about SUV, and the fact that
UV’s were calculated in only about half of the participants
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in our study, did support us not to use SUV’s. Even without
calculating SUV’s, we were able to demonstrate that tumor
extension by lymphatic and hematogenous spread as quali-
tatively imaged by elevated FDG activity on PET may best
determine prognosis.
Patients in the study were required to have NSCLC. How-
ever, bronchiolo-alveolar carcinoma (BAC) was excluded.
The performance of PET in the detection of BAC, especially
pure forms of BAC, seems to be suboptimal. The strategy to
exclude BAC from the study resulted in the exclusion of only
two patients [19].
Patients were selected for PET on the basis of history,
physical and laboratory examinations, chest X-ray, bron-
choscopy, and CT. Patients with presumed resectable disease
were selected for PET, to exclude distant metastasis and
to be informed on their mediastinal status. This strategy
excluded obvious stage IV patients with worse performance
status. The current staging strategy was developed because
PET resources were limited, especially in the beginning
of the study period, and because traditional staging with-
out PET was the gold standard for NSCLC. It was not until
recently that PET has found its place in the standardwork-up
algorithm of NSCLC in our hospital. With the present results
and the outcomes of two meta-analyses in mind, PET can
best be performed after clinical staging with chest radiogra-
phy, bronchoscopy, and CT of the chest and upper abdomen
[3,20]. Local tumor growth can reliably be assessed by CT,
which can serve as a selection of NSCLC patients for PET,
[4] Kramer H, Groen HJM. Current concepts in the mediastinal
lymph node staging of nonsmall cell lung cancer. Ann Surg
2003;238:180—8.
[5] MacManus MP, Hicks RJ. PET scanning in lung cancer:
current status and future directions. Semin Surg Oncol
2003;21:149—55.
[6] Ahuja V, Coleman RE, Herndon JE, Patz EF. The prognostic sig-
niﬁcance of ﬂuorodeoxyglucose positron emission tomography
imaging for patients with nonsmall cell lung carcinoma. Cancer
1998;83:918—24.
[7] Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Ver-
beken EK, Deneffe GJ, et al. Prognostic importance of the
standardized uptake value on (18)F-ﬂuoro-2-deoxy-glucose-
positron emission tomography scan in non-small-cell lung can-
cer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin
Oncol 1999;17:3201—6.
[8] Dhital K, Saunders CA, Seed PT, O’Doherty MJ, Dussek J.
[(18)F]Fluorodeoxyglucose positron emission tomography and
its prognostic value in lung cancer. Eur J Cardiothorac Surg
2000;18:425—8.
[9] Patz EF, Connolly J, Herndon JE. Prognostic value of thoracic
FDG PET imaging after treatment for non-small cell lung can-
cer. AJR Am J Roentgenol 2000;174:769—74.
[10] Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKen-
zie AF, et al. 18F-FDG PET provides high-impact and pow-
erful prognostic stratiﬁcation in staging newly diagnosed
non-small cell lung cancer. J Nucl Med 2001;42:1596—
604.
[11] Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et
al. 18F-FDG uptake as a biologic prognostic factor for recur-although it has to be emphasized that in our study, PET
staging was performed independently from (i.e. blinded to)
clinical stage.
5. Conclusions
In this study on prognostic factors for survival of 266 NSCLC
patients, tumor stage as determined by qualitative analy-
sis of FDG uptake as measured by PET proved to be the
most signiﬁcant prognostic factor for survival. This was
followed by ECOG performance score. Weight loss, clini-
cal tumor stage, age, sex, cardiovascular comorbidity, pul-
monary comorbidity, and tumor histology did not reach
signiﬁcance.
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